Funding
Series B · Biotech

Kinaset Therapeutics raises $103m Series B for respiratory therapies

RA Capital Management, Forge Life Science Partners and other investors participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Kinaset Therapeutics raised $103 million in Series B financing on January 10. Participants included RA Capital Management, Forge Life Science Partners, EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, Atlas Venture, 5AM Ventures and Gimv. The company develops inhaled therapies for severe respiratory diseases.

Funding history

Series B · This round$103M

Sources

  1. Kinaset Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related